title: Clinical implications of understanding radiographic findings in relation to clinical outcomes in rheumatoid arthritis.
abstract: The clinical progression of rheumatoid arthritis (RA) and longterm response to therapy is generally assessed by quantifying changes in joint space narrowing and erosions visible on serial plain radiographs. In patients treated with classic disease modifying antirheumatic drugs, the joint damage seen on radiographic images is usually directly associated with longterm functional disability. However, this relationship is not as clearly defined in patients treated with biologic agents. The apparent dissociation between clinical and radiologic outcomes in patients with RA who are treated with biologic therapies needs to be taken into consideration when evaluating the efficacy of treatment.
authors.affiliation: Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, The Joseph and Wolf Lebovic Building, 60 Murray Street, 2nd Floor, Room 2-006, Toronto, Ontario M5T 3L9. edkeystone@mtsinai.on.ca
authors.forename: Edward C
authors.initials: EC
authors.lastname: Keystone
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D001175:Arthrography; D001688:Biological Products / Q000627:therapeutic use; D002983:Clinical Competence; D032882:Comprehension; D004185:Disability Evaluation; D016903:Drug Monitoring; D006801:Humans; D007596:Joints / Q000473:pathology*; D008727:Methotrexate / Q000627:therapeutic use; D011237:Predictive Value of Tests; D012720:Severity of Illness Index; D013585:Synovitis / Q000000981:diagnostic imaging / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; D008727:Methotrexate